Jonathan Gutman, MD
Medical Oncology · Aurora, CONPI 1003882952
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $20,812 of the $26,496 with a category attached, or 78.5%. 10 manufacturers reported payments, led by Gamida Cell Inc. at 44.0% of the total. 2025 is the largest year on record at $15,960, more than ten times the $937 reported in 2019.
Across 18 payments — averaging $1472.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gamida Cell Inc.$12K
- National Marrow Donor Program$10K
- Melinta Therapeutics, LLC$2K
- Janssen Scientific Affairs, LLC$1K
- Terumo BCT, Inc.$900
- Tersera Therapeutics LLC$362
- plus $373 from 4 others
Across 221 payments — averaging $3440.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$367K
- Incyte Corporation$236K
- Bristol Myers Squibb$146K
- E.r. Squibb & Sons, L.L.C.$5K
- Janssen Research & Development, LLC$4K
- Octapharma USA, Inc.$1K
- plus $174 from 1 others
What the payments were for
- Consulting fees$20,81279%
- Speaking & faculty fees$5,00019%
- Travel & lodging$3111%
- Food & beverage$3731%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gamida Cell Inc. | 2 | $11,670 |
| National Marrow Donor Program | 4 | $10,311 |
| Melinta Therapeutics, LLC | 1 | $1,680 |
| Janssen Scientific Affairs, LLC | 1 | $1,200 |
| Terumo BCT, Inc. | 1 | $900 |
| Tersera Therapeutics LLC | 1 | $362 |
| Incyte Corporation | 1 | $125 |
| Jazz Pharmaceuticals Inc. | 1 | $125 |
| AbbVie | 5 | $86 |
| Johnson & Johnson | 1 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,496 in reported general payments places this provider in the 85th percentile of 96 medical oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 53 | $706,619 |
| RezurockBelumosudil Mesylate | 23 | $394,849 |
| Tacrolimus | 11 | $3,052 |
| Acyclovir | 78 | $2,822 |
| ValacyclovirValacyclovir Hcl | 11 | $1,399 |
| Dexamethasone | 16 | $303 |
| Pantoprazole Sodium | 19 | $82 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 25 | $79 |
| Rosuvastatin Calcium | 12 | $47 |
| Levothyroxine Sodium | 18 | $35 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $125 | $706,61953 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 96 medical oncology providers in Colorado.
Other medical oncology in Aurora
- David CamidgeAurora$648K
- Paul BunnAurora$354K
- Sapna PatelAurora$186K
- Sunnie KimAurora$81K
- Virginia BorgesAurora$68K
- Erin SchenkAurora$63K
- Karl LewisAurora$62K
- Jose PachecoAurora$50K
- Leonard GlodeAurora$49K
- Robert DoebeleAurora$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.